Reducing Hereditary Cancer Act

1. What happened and its current status: On July 23, 2025, Rep. Wasserman Schultz introduced HR4752, the Reducing Hereditary Cancer Act, which amends the Social Security Act to mandate Medicare coverage for germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation. The bill was referred to the House Energy & Commerce and Ways & Means Committees. A companion bill, S2760, was introduced in the Senate and referred to Finance. Both bills are in early-stage committee referral with no markup or floor action yet. The 119th Congress (2025-2027) has substantial time remaining for committee consideration and potential passage. 2. The money trail: The bill does not include an explicit authorization of appropriations. Instead, it operates through Medicare coverage mandate—CMS must cover germline testing as a Part B benefit under section 1861(s)(2)(KK) of the Social Security Act. This shifts funding from Medicare's existing Part B trust fund (funded by payroll taxes, premiums, and general revenue). No new tax or appropriation is created; the cost is absorbed by Medicare's existing budget. The Congressional Budget Office would need to score the cost of new testing volume, which could be significant (potentially hundreds of millions annually) but is not specified in the bill text. 3. Structural winners: Pure-play genetic testing companies and reference labs with installed hereditary cancer testing capacity are primary beneficiaries. Illumina ($ILMN) provides the NGS platforms and consumables used for germline sequencing, making it a pick-and-shovel play on volume growth. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two dominant national reference labs with established hereditary cancer panels—Medicare coverage adds a large, stable payer to their existing test menus. Guardant Health ($GH) offers germline testing via liquid biopsy, diversifying its revenue beyond the tissue-agnostic liquid biopsy market. Thermo Fisher ($TMO) supplies sequencing instruments but is more diversified; the genetic testing segment is a smaller share of total revenue. 4. Real market data analysis (from Yahoo Finance): As of April 30, 2026—nearly one year after introduction—the bill's impact is not yet priced in. Recent 7-day trends show broad weakness: ILMN -4.04% to $120.37 (near lower half of 52-week range $73.86-$155.53), LH -2.94% to $257.14, DGX -5.12% to $189.32, TMO -0.09% to $466.26. This sector weakness appears unrelated to the bill (likely broader market or earnings factors). These depressed levels could represent an entry opportunity if the bill gains legislative momentum—but the early-stage status means no near-term catalyst. 5. Timeline: The bill is in early-stage committee referral. Next steps: Energy & Commerce and Ways & Means must hold hearings and markups, then report to the House floor. The Senate companion (S2760) must move through Finance. Passage in the 119th Congress is plausible but not assured—bills with 27 cosponsors and bipartisan sponsors (Wasserman Schultz-D, Miller-Meeks-R) have moderate momentum. If passed, implementation would follow CMS rulemaking (typically 12-24 months post-enactment).